Why Farbe Firma is the Top Manufacturer of Sodium Stibogluconate Injection
- Maulik Sudani
- Jun 3
- 7 min read
Last Updated: June 3, 2026
TL;DR: Sodium Stibogluconate Injection — a sterile aqueous solution of the pentavalent antimonial antileishmanial sodium stibogluconate, supplied most commonly as a solution containing 100 mg/mL of pentavalent antimony (Sb-V) in multi-dose vials and ampoules for slow intravenous or intramuscular administration — is a first-line agent against leishmaniasis in much of the endemic world: visceral leishmaniasis (kala-azar), cutaneous leishmaniasis and mucocutaneous leishmaniasis. By delivering pentavalent antimony that is reduced in vivo to the active trivalent form and interferes with the parasite's energy metabolism and thiol redox balance, it remains a backbone of WHO leishmaniasis treatment programmes. Because antimony content, the pentavalent-to-trivalent ratio, the impurity profile and heavy-metal limits directly govern both efficacy and the drug's known cardiotoxicity, its safety depends on exact antimony assay, a tightly controlled impurity profile, low particulate and endotoxin and robust container-closure integrity. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Sodium Stibogluconate Injection at our Gujarat, India facility and supplies it to hospital pharmacy, infectious-disease and public-health services, national leishmaniasis-control programmes, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Pentavalent antimonial antileishmanial — Sodium Stibogluconate Injection is a first-line agent for visceral leishmaniasis (kala-azar), cutaneous and mucocutaneous leishmaniasis, delivering pentavalent antimony (Sb-V) that is reduced in vivo to the active trivalent form to interfere with the parasite's energy metabolism and thiol redox balance.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, qualified vial and ampoule filling lines, dedicated control of antimony assay, the pentavalent/trivalent ratio, heavy-metal limits, the impurity profile, particulate and endotoxin for an aqueous antimonial solution, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, drug master files and CEP-style documentation for registrations including ministry-of-health, neglected-tropical-disease-programme and hospital tenders.
End-to-end CDMO services: Contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tender-ready vial and ampoule packaging and logistics coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Sodium Stibogluconate Injection Demands a Premium Manufacturer
Sodium Stibogluconate Injection occupies a high-stakes place in the treatment of one of the world's most important neglected tropical diseases. It is a pentavalent antimonial that infectious-disease physicians and public-health programmes depend on when a patient presents with leishmaniasis — visceral leishmaniasis (kala-azar), which is fatal if untreated, as well as cutaneous and mucocutaneous forms. It is given over a multi-day to multi-week course by slow intravenous or intramuscular injection, often as part of nationally and WHO-coordinated control programmes in endemic regions of South Asia, East Africa and Latin America. In every one of these settings the patient is seriously ill, the treatment course is prolonged, and the dose — expressed in milligrams of pentavalent antimony per kilogram — must be both accurate and consistent from vial to vial.
That clinical reality places real demands on the manufacturer. Sodium stibogluconate is not a single, sharply defined small molecule but a complex, somewhat heterogeneous antimony-carbohydrate complex, and its therapeutic activity is defined by its pentavalent antimony content rather than by a simple molar concentration. The balance matters in both directions: too little pentavalent antimony and the course under-doses a life-threatening infection; excess trivalent antimony or heavy-metal impurity drives the well-documented cardiotoxicity, hepatotoxicity and pancreatic toxicity that make antimonial therapy demanding to deliver safely. The solution must also be clear, particulate-free, low in endotoxin and reliably sealed across a long treatment course. Choosing a Sodium Stibogluconate Injection manufacturer that treats antimony assay, the pentavalent/trivalent ratio, heavy-metal control, impurity profiling and container-closure integrity as core engineering disciplines is what protects the leishmaniasis patient at the bedside.
What Sets a World-Class Sodium Stibogluconate Injection Manufacturer Apart
A world-class manufacturer of Sodium Stibogluconate Injection invests in three areas that weaker suppliers underfund: exact quantification of pentavalent antimony content and control of the trivalent-antimony and heavy-metal impurity profile so that every batch matches the reference potency and toxicity window, robust aseptic filling of an aqueous antimonial into vials and ampoules with verified container-closure integrity, and tender-ready dossier support for a product procured almost entirely through ministry-of-health, neglected-tropical-disease-programme and hospital channels. It starts with the active — pharmacopoeial- or WHO-specification-grade sodium stibogluconate sourced from qualified, audited API makers, with full antimony-speciation, heavy-metal and impurity profiling, potency assay and certificates of analysis verified by the receiving laboratory before the material enters production.
Formulation, filling and sealing then have to preserve both the antimony content and the dose. The bulk solution is compounded in water-for-injection at controlled pH, sterile-filtered through 0.22 µm membrane and filled aseptically into clear-glass vials and ampoules under ISO Class 5 air. The filling and sealing parameters are locked in the master batch record, because the antimony assay and the pentavalent/trivalent ratio govern both the efficacy and the safety margin of an antimonial. Vials are sealed under controlled headspace and ampoules are fusion-sealed and 100 % inspected; in-process and release testing confirm pentavalent antimony content by validated assay, the heavy-metal and impurity profile, pH, clarity and colour of the solution, and endotoxin is held well within limits so the diluted or undiluted injection is safe for slow administration over a long course.
Quality Systems Behind Every Sodium Stibogluconate Injection
Every Farbe Firma Sodium Stibogluconate Injection batch is released only after a full stack of quality checks: validated antimony assay (total and pentavalent antimony, with control of the trivalent fraction) by techniques such as atomic absorption or ICP against USP, BP, IP or EP and WHO reference standards, heavy-metal and elemental-impurity control per ICH Q3D, control of related substances, pH and osmolarity, clarity and colour of the solution, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, fill-volume verification and container-closure integrity for the vial and ampoule formats. Certificates of analysis are issued with full traceability back to the API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, calibrated sterilisation and depyrogenation equipment, validated vial and ampoule filling lines with 100 % inspection, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because the therapeutic and toxic profile of an antimonial is defined by its pentavalent antimony content and its trivalent and heavy-metal impurities, we treat the antimony assay and the elemental-impurity result as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (30 °C / 65 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with ICH Q1B photostability challenge, and the product is protected from light and heat through its primary and secondary packaging.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Sodium Stibogluconate Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables across anti-infective, antiparasitic, critical-care, oncology-supportive and supportive-care categories. For Sodium Stibogluconate Injection specifically, we supply solution presentations standardised on pentavalent antimony content (commonly 100 mg/mL Sb-V) in multi-dose vials and ampoules under WHO-GMP conditions, with country-specific fill volumes and pack configurations available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the antimony-assay and elemental-impurity data package — ready to hand for registration and for neglected-tropical-disease tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national programme procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, antimony-assay and related-substances method-validation data, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics. When a buyer or a leishmaniasis-control programme needs Sodium Stibogluconate Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, filling-line slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the filling suite; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API antimony-speciation sourcing, assay development, heavy-metal and impurity control, particulate and endotoxin control, container-closure integrity, photostability and shelf-life choices in real detail. For a pentavalent antimonial given over a long course to seriously ill leishmaniasis patients, where antimony content and impurity control directly govern both cure and cardiotoxicity, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Sodium Stibogluconate Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Sodium Stibogluconate Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, qualified vial and ampoule filling lines, qualified water-for-injection systems, 100 % ampoule inspection and continuous environmental monitoring.
Which strengths and pack sizes of Sodium Stibogluconate Injection do you supply?
Our standard presentation is a sterile solution standardised on pentavalent antimony content (commonly 100 mg/mL Sb-V) in multi-dose vials and ampoules. Custom fill volumes, vial and ampoule counts per pack and country-specific artwork are available under contract manufacturing agreements.
Can Farbe Firma support country-specific registrations for Sodium Stibogluconate Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, antimony-assay and related-substances method-validation data, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and neglected-tropical-disease tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
How does Farbe Firma assure the quality and safety of Sodium Stibogluconate Injection?
We quantify total and pentavalent antimony content by validated assay and control the trivalent fraction, control heavy metals and elemental impurities per ICH Q3D, verify pH, clarity and colour, hold endotoxin well within limits by LAL, run particulate and sterility testing, 100 %-inspect every ampoule, verify container-closure integrity, protect the product from light and heat, and qualify each batch against ICH Q1A and ICH Q1B protocols.
What is the minimum order quantity for Sodium Stibogluconate Injection contract manufacturing?
MOQs vary by vial or ampoule size, fill volume, label complexity and dossier requirements. For our vial and ampoule presentations we accommodate hospital-scale and full national-programme-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments